Skip to content

Coordinated circRNA Silencing and Chemotherapy by pH-Responsive Nanoparticles Reprogram Cell Death in Drug-Resistant Osteosarcoma.

Aug 2026 · Nano letters (Print) · Vol 26 34, pp. 11420-11431 · 0 citations · 68 references
Medicine

Abstract

Chemoresistance remains a major clinical challenge in osteosarcoma, primarily driven by inefficient drug delivery and the evasion of cell death. Here, a multifunctional poly(β-amino ester) (pBAE)-based therapeutic delivery system was developed for simultaneous codelivery of small interfering RNA (siRNA) and doxorubicin (DOX) to drug-resistant osteosarcoma cells. The system significantly enhanced siRNA transfection within 4 h and showed substantially enhanced cytotoxicity compared with free DOX at equivalent concentrations. Mechanistically, pBAE degraded in the acidic tumor microenvironment, facilitating siRNA and DOX release, which synergistically modulated apoptotic and pyroptotic signaling to induce cell death. In vivo studies in osteosarcoma-bearing mice demonstrated that pBAE-based treatment markedly suppressed tumor growth, reducing tumor volume by approximately 70% without significant adverse effects. This study presents a therapeutic strategy centered on the "enhanced delivery-induced cell death" paradigm, effectively overcoming osteosarcoma chemoresistance and designing multifunctional nanodelivery systems for cancer therapy.

View source

Similar papers

Oct 2026

A dual-targeted, pH-sensitive cationic liposomal system co-delivering paclitaxel and siCXCR2 for synergistic inhibition of lung cancer cells in vitro.

Lung cancer remains the most commonly diagnosed malignancy and a leading cause of cancer-related mortality worldwide. Paclitaxel (PTX), a first-line chemotherapeutic agent for advanced non-small cell lung cancer (NSCLC), is frequently compromised by acquired drug resistance. Here, through network pharmacology analysis...

Ze-Jin Shen, Xu-Ran Kou, Ming-Yuan Wang et al. · 0 citations
Open access Sep 2026

CPT-TCPP polymeric nanoplatform for sonodynamic-chemotherapy synergistic tumor therapy through ferroptosis-apoptosis dual cell death reprogramming

Traditional cancer therapies are constrained by tumor diversity, therapeutic resistance, and side effects, thereby necessitating the development of precise multimodal antitumor strategies. This work reports a relatively high-drug-loading polymeric nanoplatform, PSCT, for combined sonodynamic therapy and chemotherapy. C...

Lu Wang, Zhi-Bo Zhang, Qiao-Ni Liu et al. · 0 citations
Open access Sep 2026

Targeted dual-responsive nanocapsules for synergistic cisplatin and paclitaxel prodrug delivery in the treatment of lung cancer

Background The clinical application of traditional chemotherapy for treating patients with lung cancer is restricted by its poor targeting efficacy and severe systemic toxicity. In this study, we developed an acid-sensitive lipid-polymer nanocapsule (PTX/Pt@RGD) for the co-delivery of a redox-sensitive paclitaxel (PTX)...

Xin-Yue Wang, Dan Qin, Chun-Yu Yao et al. · 0 citations
Oct 2026

Tumor-Microenvironment-Responsive Nanosystem for Enhanced Melanoma Immunotherapy via Dual Epigenetic Regulation and Cuproptosis

As a highly malignant tumor, melanoma is associated with poor prognosis and high recurrence rates. Despite advances in surgery, radiotherapy, chemotherapy, and immunotherapy, drug resistance and immune evasion remain major obstacles. Epigenetic dysregulationsuch as aberrant DNA methylation and histone deacetylation...

Yue-Zhu Zhao, Jie Ma, Yue Xu et al. · 0 citations
Open access Oct 2026

Combination of Organoselenium-Loaded Nanoparticles and Conventional Chemotherapeutics Synergistically Enhances Antitumor Efficacy and Modulates Multidrug Resistance: An In Vitro Study

Background/Objectives: Cancer causes high premature death worldwide, with 35 million new cases expected by 2050. Multidrug resistance (MDR), driven by genetic and epigenetic changes, hampers chemotherapy. In this study, polymeric nanoparticles (NPs) were formulated with an organoselenium nucleoside analogue (AFAT-Se) t...

Bruna Fracari Do Nascimento, Bianca Costa Maia-do-Amaral, Taís Baldissera Pieta et al. · 0 citations
Open access Sep 2026

CD73 disruption with tumor-specific CRISPR/Cas9 nanoparticles reduces adenosine-mediated immunosuppression and amplifies response to chemotherapy

The therapeutic efficacy of cancer immunotherapy is impaired by poor tumor immunogenicity and the immunosuppressive tumor microenvironment (TME), partially driven by reprogrammed adenosine metabolism in the tumor. Here, we develop degradable CRISPR/Cas9 nanoparticles to durably and precisely downregulate CD73 expressio...

Xin-Hong Sun, Yu-Jing Sang, Teng-Fei He et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.